Open Access<p>Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis</p>
Author(s) -
Katrina Wilcox Hagberg,
Rebecca Persson,
Catherine VasilakisScaramozza,
Steve J. Niemcryk,
Michael Peng,
Maria Paris,
Anders Lindholm,
Susan S. Jick
Publication year - 2020
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s239511
Subject(s) - medicine , apremilast , psoriatic arthritis , psoriasis , population , tuberculosis , tofacitinib , gastroenterology , immunology , dermatology , rheumatoid arthritis , environmental health , pathology
Psoriasis and psoriatic arthritis (PsA) are associated with an increased infection risk. In this cohort study of patients with treated psoriasis or PsA, we used MarketScan (2014-2018) to estimate rates of herpes zoster, hepatitis C (HepC) and tuberculosis (TB) with apremilast compared to other systemic treatments.